SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97: 13344.
  • 2
    Drewe E, McDermott EM, Powell PT, Isaacs JD, Powell RJ. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients [published erratum appears in Rheumatology (Oxford) 2003;42:711]. Rheumatology (Oxford) 2003; 42: 2359.
  • 3
    Church LD, Churchman SM, Hawkins PN, McDermott MF. Hereditary auto-inflammatory disorders and biologics. Springer Semin Immunopathol 2006; 27: 494508.
  • 4
    Drewe E, Powell RJ, McDermott EM. Comment on: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS) [letter]. Rheumatology (Oxford) 2007; 46: 18656.
  • 5
    Jacobelli S, Andre M, Alexandra JF, Dode C, Papo T. Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS) [letter]. Rheumatology (Oxford) 2007; 46: 12112.
  • 6
    Siebert S, Amos N, Lawson TM. Comment on: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS) [letter]. Rheumatology (Oxford) 2008; 47: 2289.
  • 7
    Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001; 121: 114557.
  • 8
    Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, et al. Evidence that anti–tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 2005; 52: 6172.
  • 9
    Shen C, Assche GV, Colpaert S, Maerten P, Geboes K, Rutgeerts P, et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005; 21: 2518.
  • 10
    Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003; 114: 18190.
  • 11
    Muppidi JR, Tschopp J, Siegel RM. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity 2004; 21: 4615.
  • 12
    Schneider-Brachert W, Tchikov V, Neumeyer J, Jakob M, Winoto-Morbach S, Held-Feindt J, et al. Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 2004; 21: 41528.
  • 13
    D'Osualdo A, Ferlito F, Prigione I, Obici L, Meini A, Zulian F, et al. Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor–induced apoptosis: pathogenetic and clinical implications. Arthritis Rheum 2006; 54: 9981008.
  • 14
    Bernard D, Quatannens B, Begue A, Vandenbunder B, Abbadie C. Antiproliferative and antiapoptotic effects of cRel may occur within the same cells via the up-regulation of manganese superoxide dismutase. Cancer Res 2001; 61: 265664.
  • 15
    Sanjabi S, Hoffmann A, Liou HC, Baltimore D, Smale ST. Selective requirement for c-Rel during IL-12 P40 gene induction in macrophages. Proc Natl Acad Sci U S A 2000; 97: 1270510.
  • 16
    Ryan J, Balow J Jr, Barham B, Barron K, Kastner DL, Aksentijevich I. Identification and analysis of gene-expression signatures in peripheral blood leukocytes of patients with TRAPS [abstract]. Clin Exp Rheumatol 2008; 26: 182.
  • 17
    Aksentijevich I, Galon J, Soares M, Mansfield E, Hull K, Oh HH. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 2001; 69: 30114.
  • 18
    Nedjai B, Hitman GA, Yousaf N, Chernajovsky Y, Stjernberg-Salmela S, Pettersson T, et al. Abnormal tumor necrosis factor receptor I cell surface expression and NF-κB activation in tumor necrosis factor receptor–associated periodic syndrome. Arthritis Rheum 2008; 58: 27383.
  • 19
    Stjernberg-Salmela S, Pettersson T, Karenko L, Blazevic V, Nevala H, Pitkanen S, et al. A novel tumour necrosis factor receptor mutation in a Finnish family with periodic fever syndrome. Scand J Rheumatol 2004; 33: 1404.
  • 20
    Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, et al. Binding and functional comparison of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301: 41826.
  • 21
    Evans TJ, Moyes D, Carpenter A, Martin R, Loetscher H, Lesslauer W, et al. Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of sepsis. J Exp Med 1994; 180: 21739.
  • 22
    Huggins ML, Radford PM, McIntosh RS, Bainbridge SE, Dickinson P, Draper-Morgan KA, et al. Shedding of mutant tumor necrosis factor receptor superfamily 1A associated with tumor necrosis factor receptor–associated periodic syndrome: differences between cell types. Arthritis Rheum 2004; 50: 26519.